VEGF and IL-6 correlation in POEMS: a potential upcoming marker of active disease and early autologous BMT response.

Main Article Content

Luca Laurenti
Idanna Innocenti
Giulia Benintende
Annamaria Tomasso
Francesco Autore
Alberto Fresa
Florenzia Vuono
Silvia Baroni
Claudia Giannotta
Patrizia Chiusolo
Federica Sorà
Simona Sica




Introduction: VEGF function may be responsible for most POEMS manifestations, and it is considered a reliable marker of disease. COVID-19 era arose increasing interest for other inflammatory cytokines, with particular focus on Interleukin-6; VEGF production is stimulated by IL-6 and IL1β, whose concentrations appear to be elevated in clonal plasma cells.

Objectives: This study aims to simultaneously evaluate VEGF and IL-6 values in patients (pts) with POEMS at different stages of the disease to find a correlation between them.

Methods: We performed a monocentric study, measuring serum levels of VEGF and IL-6 in 8 POEMS pts at different time points of the disease.

Results: We observed elevated serum levels of both VEGF and IL-6 in three pts before transplant, while the day after the infusion of autologous stem cells, we observed a steep decrease of both serum markers. Among the four-pts tested only after transplant, two presented with a consensual level of VEGF and IL-6, while the others did not correlate. One patient observed at POEMS diagnosis, during active disease, presented with strikingly high levels of both serum markers.

Conclusions: So far, to the best of our knowledge, IL-6 could be considered as a marker of active disease and reliable up to the very first months after BMT, after which its accuracy appears to be lost due to unknown factors, still to be investigated.


Download data is not yet available.

Abstract 906
PDF Downloads 364
HTML Downloads 152


1. Dispenzieri A. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2019 Jul;94(7):812-827. doi: 10.1002/ajh.25495. Epub 2019 May 23. PMID: 31012139.
2. Soubrier M, Dubost JJ, Serre AF, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum. 1997 Apr;40(4):786-7. doi: 10.1002/art.1780400430. PMID: 9125266.
3. Tzeng HE, Tsai CH, Chang ZL, et al. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol. 2013;85(4):531-540. doi:10.1016/j.bcp.2012.11.021
4. Gherardi RK, Bélec L, Fromont G, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood. 1994;83(9):2587-2593.
5. Fukatsu A, Ito Y, Yuzawa Y, et al. A case of POEMS syndrome showing elevated serum interleukin 6 and abnormal expression of interleukin 6 in the kidney. Nephron. 1992;62(1):47-51. doi:10.1159/000186994
6. Minamitani S, Ohfuji S, Nishiguchi S, et al. An autopsy case of POEMS syndrome with a high level of IL-6 and VEGF in the serum and ascitic fluid. Intern Med. 2002;41(3):233-236. doi:10.2169/internalmedicine.41.233
7. Fukatsu A, Ito Y, Yuzawa Y, et al. A case of POEMS syndrome showing elevated serum interleukin 6 and abnormal expression of interleukin 6 in the kidney. Nephron. 1992;62(1):47-51. doi:10.1159/000186994
8. Hitoshi S, Suzuki K, Sakuta M. Elevated serum interleukin-6 in POEMS syndrome reflects the activity of the disease. Intern Med. 1994;33(10):583-587. doi:10.2169/internalmedicine.33.583
9. Laurenti L, De Matteis S, Sabatelli M, et al. Early diagnosis followed by front-line autologous peripheral blood stem cell transplantation for patients affected by POEMS syndrome. Leuk Res. 2008 Aug;32(8):1309-12. doi: 10.1016/j.leukres.2007.11.029. Epub 2008 Jan 22. PMID: 18207237.
10. Yoshizaki K, Murayama S, Ito H, Koga T. The Role of Interleukin-6 in Castleman Disease. Hematol Oncol Clin North Am. 2018;32(1):23-36. doi:10.1016/j.hoc.2017.09.003